The European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, has issued a positive opinion recommending that Pepaxti (melflufen), in combination with dexamethasone, be approved for adults with multiple myeloma who have received at least two previous lines of therapy and whose disease is refractory to lenalidomide and their most recent treatment.
Pepaxti gets regulatory boost – Oncopeptides shares jump
Oncopeptides is moving closer to expanding the use of its multiple myeloma drug Pepaxti in Europe. The Swedish biotech company’s shares rose by around 20 per cent in early trading on Friday following the regulatory announcement.
Advertisement
BREAKING